Safarinejad et al. randomized 228 patients with early chronic disease to receive either 400 mg sustained-release pentoxifylline or placebo twice daily for 6 months. Individuals were assessed for ...
A double-blind, randomized, six-month study by Roekaerts and Deleers [39] assessed the efficacy and safety of pentoxifylline 400 mg three times daily versus placebo in 36 patients with IC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback